ECSP10010247A - Derivados heterocíclicos - Google Patents
Derivados heterocíclicosInfo
- Publication number
- ECSP10010247A ECSP10010247A EC2010010247A ECSP10010247A ECSP10010247A EC SP10010247 A ECSP10010247 A EC SP10010247A EC 2010010247 A EC2010010247 A EC 2010010247A EC SP10010247 A ECSP10010247 A EC SP10010247A EC SP10010247 A ECSP10010247 A EC SP10010247A
- Authority
- EC
- Ecuador
- Prior art keywords
- heterocyclic derivatives
- relates
- present
- heterocyclic
- solvate
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009782 synaptic response Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se relaciona con un derivado heterocíclico de acuerdo a la fórmula I), donde las variables se definen como en la memoria, o con una sal o solvato farmacéuticamente aceptable del mismo. La presente invención también se relaciona con una composición farmacéutica que comprende dichos derivados heterocíclicos y su uso en terapia, por ejemplo en el tratamiento o prevención de enfermedades siquiátricas donde se requiere un aumento de las respuestas sinápticas mediadas por los receptores de AMPA, incluyendo esquizofrenia, depresión y mal de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120603 | 2007-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010247A true ECSP10010247A (es) | 2010-07-30 |
Family
ID=39472607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010247A ECSP10010247A (es) | 2007-11-13 | 2010-06-11 | Derivados heterocíclicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8129397B2 (es) |
| EP (1) | EP2209791B1 (es) |
| JP (1) | JP5455130B2 (es) |
| KR (1) | KR20100106370A (es) |
| CN (1) | CN101855227B (es) |
| AR (1) | AR069286A1 (es) |
| AU (1) | AU2008322986B2 (es) |
| BR (1) | BRPI0819202A2 (es) |
| CA (1) | CA2703901C (es) |
| CL (1) | CL2008003362A1 (es) |
| CO (1) | CO6270365A2 (es) |
| EC (1) | ECSP10010247A (es) |
| MX (1) | MX2010004686A (es) |
| PE (1) | PE20091167A1 (es) |
| RU (1) | RU2010123895A (es) |
| TW (1) | TW200934497A (es) |
| WO (1) | WO2009062930A1 (es) |
| ZA (1) | ZA201002580B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス，インコーポレーテッド | ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 |
| EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| AR115905A1 (es) | 2018-08-03 | 2021-03-10 | Cadent Therapeutics Inc | 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2541458C (en) * | 2003-10-08 | 2011-09-20 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| ES2383115T3 (es) | 2004-01-09 | 2012-06-18 | Eli Lilly And Company | Compuestos de tiofeno y furano |
| CA2601098C (en) * | 2005-03-16 | 2011-07-05 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
| GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| CA2612176C (en) * | 2005-06-14 | 2015-02-17 | Aska Pharmaceutical Co., Ltd. | Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
-
2008
- 2008-10-28 TW TW097141383A patent/TW200934497A/zh unknown
- 2008-11-11 WO PCT/EP2008/065306 patent/WO2009062930A1/en not_active Ceased
- 2008-11-11 MX MX2010004686A patent/MX2010004686A/es not_active Application Discontinuation
- 2008-11-11 AU AU2008322986A patent/AU2008322986B2/en active Active
- 2008-11-11 EP EP08849917.3A patent/EP2209791B1/en active Active
- 2008-11-11 CN CN2008801156861A patent/CN101855227B/zh active Active
- 2008-11-11 RU RU2010123895/04A patent/RU2010123895A/ru unknown
- 2008-11-11 BR BRPI0819202 patent/BRPI0819202A2/pt not_active IP Right Cessation
- 2008-11-11 KR KR1020107012728A patent/KR20100106370A/ko not_active Withdrawn
- 2008-11-11 JP JP2010533556A patent/JP5455130B2/ja active Active
- 2008-11-11 CA CA2703901A patent/CA2703901C/en active Active
- 2008-11-12 CL CL2008003362A patent/CL2008003362A1/es unknown
- 2008-11-12 PE PE2008001915A patent/PE20091167A1/es not_active Application Discontinuation
- 2008-11-12 AR ARP080104926A patent/AR069286A1/es unknown
- 2008-11-12 US US12/269,306 patent/US8129397B2/en active Active
-
2010
- 2010-04-13 ZA ZA2010/02580A patent/ZA201002580B/en unknown
- 2010-05-13 CO CO10057470A patent/CO6270365A2/es not_active Application Discontinuation
- 2010-06-11 EC EC2010010247A patent/ECSP10010247A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101855227A (zh) | 2010-10-06 |
| AR069286A1 (es) | 2010-01-13 |
| JP2011503139A (ja) | 2011-01-27 |
| AU2008322986A1 (en) | 2009-05-22 |
| CA2703901A1 (en) | 2009-05-22 |
| RU2010123895A (ru) | 2011-12-20 |
| CN101855227B (zh) | 2013-01-23 |
| PE20091167A1 (es) | 2009-08-03 |
| CA2703901C (en) | 2016-05-10 |
| AU2008322986B2 (en) | 2013-08-01 |
| CO6270365A2 (es) | 2011-04-20 |
| MX2010004686A (es) | 2010-05-19 |
| KR20100106370A (ko) | 2010-10-01 |
| JP5455130B2 (ja) | 2014-03-26 |
| BRPI0819202A2 (pt) | 2015-05-05 |
| ZA201002580B (en) | 2010-12-29 |
| TW200934497A (en) | 2009-08-16 |
| CL2008003362A1 (es) | 2009-06-26 |
| EP2209791A1 (en) | 2010-07-28 |
| WO2009062930A1 (en) | 2009-05-22 |
| US20090131455A1 (en) | 2009-05-21 |
| EP2209791B1 (en) | 2014-01-22 |
| US8129397B2 (en) | 2012-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010247A (es) | Derivados heterocíclicos | |
| BR112012008518A2 (pt) | derivado heterocíclico, e, composição farmacêutica | |
| HN2012001413A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
| CL2008002542A1 (es) | Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| UY31676A1 (es) | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
| DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
| GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
| ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona | |
| PA8627201A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| CR10420A (es) | Derivados biciclicos como inhibibidores de cetp | |
| ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
| CO6491058A2 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| GT200800189A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| MX336774B (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida. | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| AR061792A1 (es) | Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| ECSP11010992A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 |